BioMarin Pharm: License For Naglazyme Submitted In Japan (Japan)
This article was originally published in PharmAsia News
BioMarin Pharmaceutical Inc. said Anges MG Inc. submitted a biologics license application to the Japanese Ministry of Health, Labour, and Welfare for its Naglazyme drug to treat Maroteaux-Lamy syndrome. The biopharmaceutical company established its marketing and distribution agreement with AnGes in December 2006. Final results for a Phase III trial of BioMarin's Kuvan drug were published in The Lancet. The study suggested that treatment with Kuvan resulted in significant reductions in blood Phe levels in some phenylketonuria patients. (Click here for more - May Require Paid Subscription
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.